Testosterone undecanoate 1000 mg at 3 months does not increase Prostatic Specific Antigen level. Study on over 100 patients – December 2012

Matei Pisoschi 1, Mara Carsote 2, Catalina Poiana 2, Cristina Daniela Staicu 3, Dan Perețianu 3
1. Department of Urology, “Panduri-Burghele” Hospital, 2. SCM “Povonei”, Bucharest – Romania

**Aim.** To find if testosterone undecanoate 1000 mg injection (Nebido®; Bayer-Schering) has a negative effect on prostate.

**Material&Method.** 1. PSA (ng/ml) was registered retrospective (from files) and prospective analysis (onset 2010). 2. From over 200 patients to whom testosterone undecanoate 1000 mg, i.m. was administrated at 3 months, in the last 7 years, and to whom the prostatic volume was quantified, 2096 PSA analysis were done before and after treatment. PSA was recorded (if possible) at T1 to T10 [2 weeks to 7 years] (see Pisoschi, this Congress); at least two analysis were registered. 3. None patient with prostatic cancer was included. 4. **Statistical analysis:** Student test, simple correlation, multiple regression.

**Results.** A. Patients at onset: 143 men, 18–96 years, average: 60.38; median: 60. B. Prostatic volume (cmc): average: 34.81. C. Average PSA (no pts): a. before treatment = 1,60 (143); 1y = 1,69 (99); 2y = 1,4 (73); 3y = 1,85 (48); 4y = 2 (38); 5y = 1,86 (26); 6y = 1,51 (10); 7y = 2,86 (6).

**Conclusions.** 1. Testosterone undecanoat 1000 mg injectable i.m. at 3 months does not increase significantly PSA level after 7 years administrations. 2. PSA level post testosterone was in fact dependent on age, prostatic volume before treatment and the level before testosterone administration.